Crossmark

Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report

Crossref DOI link: https://doi.org/10.1007/s10637-025-01564-1

Published Online: 2025-07-31

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takakura, Toshiaki

Iwasa, Tsutomu

Imamura, Chiyo K.

Watanabe, Satomi

Hayashi, Hidetoshi
License Information

Text and Data Mining valid from 2025-07-31

Version of Record valid from 2025-07-31
More Information

Article History

Received: 3 April 2025

Accepted: 4 July 2025

First Online: 31 July 2025

Declarations

:

: The patient provided written informed consent and the study protocols were approved by Kindai University Hospital.

: The patient declared to consent to participate in this study.

: Written informed consent was obtained from the patient for the publication of medical data.

: Hidetoshi Hayashi: Grants or contracts from Pfizer R & D Japan G.K., Pfizer Japan Inc., AstraZeneca K.K.; payment or honoraria from Pfizer Japan Inc., AstraZeneca K.K.; advisory board roles from AstraZeneca K.K. The remaining authors declare that they have no competing interests.

Document is current

Any future updates will be listed below